Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAURA2: osimertinib with or without platinum plus pemetrexed in first-line EGFR-mutated advanced non-small cell lung cancer
2023-508800-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of osimertinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Sep 2020; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508800-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508800-39-00.